Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections

Seminars in Immunology

Volumn 25, Issue 3, 2013, Pages 240-248

  Tam, Vincent C ^a  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Anti inflammatory; Borrelia burgdorferi; E. coli; Influenza; Lipid mediators; Lipidomic analysis; Lyme disease; Mass spectrometry; Peritonitis; Pro resolution; Proinflammatory; Systems biology

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CHEMOATTRACTANT; CYCLOOXYGENASE 2; CYTOCHROME P450; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LEUKOTRIENE B4; LEUKOTRIENE E4; LINOLENIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; THROMBOXANE A2; TOLL LIKE RECEPTOR 4; VANCOMYCIN; ZYMOSAN;

2009 H1N1 INFLUENZA; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL WALL; BORRELIA BURGDORFERI; BRONCHOSPASM; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CYTOKINE STORM; DIARRHEA; DNA VIRUS INFECTION; EARLY RESPONSE GENE; ELECTROSPRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART FAILURE; HELPER CELL; HEMOCONCENTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHERMIA; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INNATE IMMUNITY; LEGIONELLA PNEUMOPHILA; LEUKOCYTE ADHERENCE; LIGAND BINDING; LIPID METABOLISM; LIPIDOMICS; LUNG EDEMA; LYME DISEASE; MASS SPECTROMETRY; MOUSE STRAIN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OSTEOARTHRITIS; PERITONEUM MACROPHAGE; PERITONITIS; PLEURISY; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RNA VIRUS INFECTION; SENSITIVITY AND SPECIFICITY; SENSORY NERVE CELL; SKIN INFECTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; SOLID PHASE EXTRACTION; STAPHYLOCOCCUS AUREUS; SYSTEMS BIOLOGY; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TISSUE INJURY; VASODILATATION; VIRUS INFECTION;

AA; AIM2-LIKE RECEPTOR; ALR; ANTI-INFLAMMATORY; ARACHIDONIC ACID; BORRELIA BURGDORFERI; CFU; COLONY FORMING UNITS; COX; CYCLOOXYGENASE; CYP450; CYTOCHROME P450; DDXS/DHXS; DEXD/H BOX PROTEINS; DHA; DIHETRE; DIHOME; DIHYDROXY-EICOSATRIENOIC ACIDS; DIHYDROXY-OCTADECENOIC ACIDS; DOCOSAHEXAENOIC ACIDS; E. COLI; EET; EICOSAPENTAENOIC ACID; ELECTROSPRAY IONIZATION; EPA; EPOME; EPOXY-EICOSATRIENOIC ACIDS; EPOXY-OCTADECENOIC ACIDS; ESI; GAS CHROMATOGRAPHY COUPLED WITH MASS SPECTROMETRY; GM-MS; HDOHE; HEPE; HEPOXILIN A3/B3; HETE; HIGH PERFORMACE LIQUID CHROMATOGRAPHY; HODE; HOTRE; HPLC; HXA(3)/B(3); HYDROX-EICOSAPENTAENOIC ACIDS; HYDROXY-DOCOSAHEXAENOIC ACID; HYDROXY-EICOSATETRAENOIC ACIDS; HYDROXY-OCTADECADIENOIC ACIDS; HYDROXY-OCTADECATRIENOIC ACIDS; INFLUENZA; INHIBITOR OF KAPPA B; IΚB; LC-MS; LEUKOTRIENE; LIPID MEDIATORS; LIPIDOMIC ANALYSIS; LIPOXIN A4/B4; LIPOXYGENASE; LIQUID CHROMATOGRAPHY COUPLED WITH MASS SPECTROMETRY; LOX; LT; LXA(4)/B(4); LYME DISEASE; MASS SPECTROMETRY; MRM; MULTIPLE REACTION MONITORING; NFΚB; NLR; NOD-LIKE RECEPTOR; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; NSAIDS; NUCLEAR FACTOR KAPPA B; OXO-OCTADECADIENOIC ACID; OXOODE; PAF; PATTERN RECOGNITION RECEPTORS; PD1; PERITONITIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PG; PLATELET-ACTIVATING FACTOR; PMN; POLYMORPHONUCLEAR CELLS; PPAR; PRO-RESOLUTION; PROINFLAMMATORY; PROSTAGLANDIN; PROTECTIN D1; PRRS; RIG-I LIKE RECEPTOR; RLR; SYSTEMS BIOLOGY; THROMBOXANE A2/B2; TLR; TNF; TOLL-LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TXA(2)/B(2); UDP; URIDINE 5′-DIPHOSPHATE;

ANIMALS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HOMEOSTASIS; HUMANS; INFECTION; LIPID METABOLISM; MACROPHAGES; MASS SPECTROMETRY; NEUTROPHILS; SYSTEMS BIOLOGY;

EID: 84887611445     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.08.006     Document Type: Review

References (92)

1. Lawrence T., Willoughby D.A., Gilroy D.W. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002, 2:787-795.
2. Quehenberger O., Dennis E.A. The human plasma lipidome. N Engl J Med 2011, 365:1812-1823.
3. Buczynski M., Dumlao D., Dennis E. An integrated omics analysis of eicosanoid biology. J Lipid Res 2009, 50:1015-1038.
4. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008, 8:349-361.
5. Norris P.C., Dennis E.A. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc Natl Acad Sci USA 2012, 109:8517-8522.
6. Ong C.K.S., Lirk P., Tan C.H., Seymour R.A. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007, 5:19-34.
7. Riccioni G., Vecchia Della R., Di Ilio C., D'Orazio N. Effect of the two different leukotriene receptor antagonists, montelukast and zafirlukast, on quality of life: a 12-week randomized study. Allergy Asthma Proc 2004, 25:445-448.
8. Serhan C.N., Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 2009, 153:S200-S215.
9. Fedson D.S. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013, 99:417-435.
10. Ma Y., Wen X., Peng J., Lu Y., Guo Z., Lu J. Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality. PLoS ONE 2012, 7:e51548.
11. Spite M., Serhan C.N. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010, 107:1170-1184.
12. Karp C.L., Flick L.M., Park K.W., Softic S., Greer T.M., Keledjian R., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004, 5:388-392.
13. Spite M., Norling L.V., Summers L., Yang R., Cooper D., Petasis N.A., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1291.
14. Gewirtz A.T., Collier-Hyams L.S., Young A.N., Kucharzik T., Guilford W.J., Parkinson J.F., et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 2002, 168:5260-5267.
15. Harizi H., Corcuff J.-B., Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008, 14:461-469.
16. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011, 31:986-1000.
17. Harris S.G., Padilla J., Koumas L., Ray D., Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol 2002, 23:144-150.
18. Spector A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 2008, 50:S52-S56.
19. Holtzman M.J. Arachidonic acid metabolism in airway epithelial cells. Annu Rev Physiol 1992, 54:303-329.
20. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
21. Sha W., Brüne B., Weigert A. The multi-faceted roles of prostaglandin E2 in cancer-infiltrating mononuclear phagocyte biology. Immunobiology 2012, 217:1225-1232.
22. Joo M., Sadikot R.T. PGD synthase and PGD2 in immune resposne. Mediators Inflamm 2012, 2012:503128.
23. Scher J.U., Pillinger M.H. The anti-inflammatory effects of prostaglandins. J Investig Med 2009, 57:703-708.
24. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001, 2:612-619.
25. Peters-Golden M., Gleason M.M., Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006, 36:689-703.
26. Bittleman D.B., Casale T.B. 5-Hydroxyeicosatetraenoic acid (HETE)-induced neutrophil transcellular migration is dependent upon enantiomeric structure. Am J Respir Cell Mol Biol 1995, 12:260-267.
27. Kronke G., Katzenbeisser J., Uderhardt S., Zaiss M.M., Scholtysek C., Schabbauer G., et al. 12/15-Lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol 2009, 183:3383-3389.
28. Jankov R.P., Luo X., Demin P., Aslam R., Hannam V., Tanswell A.K., et al. Hepoxilin analogs inhibit bleomycin-induced pulmonary fibrosis in the mouse. J Pharmacol Exp Ther 2002, 301:435-440.
29. Schwab J.M., Serhan C.N. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006, 6:414-420.
30. Bednar M.M., Gross C.E., Russell S.R., Fuller S.P., Ahern T.P., Howard D.B., et al. 16(R)-hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery 2000, 47. 1410-8-discussion1418-9.
31. Thomson S.J., Askari A., Bishop-Bailey D. Anti-inflammatory effects of epoxyeicosatrienoic acids. Int J Vasc Med 2012, 2012:605101.
32. Wray J.A., Sugden M.C., Zeldin D.C., Greenwood G.K., Samsuddin S., Miller-Degraff L., et al. The epoxygenases CYP2J2 activates the nuclear receptor PPARα in vitro and in vivo. PLoS ONE 2009, 4:e7421.
33. Deng Y., Theken K.N., Lee C.R. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 2010, 48:331-341.
34. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
35. Morin C., Sirois M., Echave V., Gomes M.M., Rousseau E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol 2008, 38:192-201.
36. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002, 196:1025-1037.
37. Groeger A.L., Cipollina C., Cole M.P., Woodcock S.R., Bonacci G., Rudolph T.K., et al. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat Chem Biol 2010, 6:433-441.
38. Lima-Garcia J.F., Dutra R.C., da Silva K., Motta E.M., Campos M.M., Calixto J.B. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br J Pharmacol 2011, 164:278-293.
39. Serhan C.N., Yang R., Martinod K., Kasuga K., Pillai P.S., Porter T.F., et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009, 206:15-23.
40. Serhan C.N., Krishnamoorthy S., Recchiuti A., Chiang N. Novel anti-inflammatory - pro-resolving mediators and their receptors. Curr Top Med Chem 2011, 11:629-647.
41. Das U.N. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006, 1:420-439.
42. Ishizaki T., Ozawa T., Voelkel N.F. Leukotoxins and the lung. Pulm Pharmacol Ther 1999, 12:145-155.
43. Ishizaki T., Shigemori K., Nakai T., Miyabo S., Ozawa T., Chang S.W., et al. Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase. Am J Physiol 1995, 269:L65-L70.
44. Totani Y., Saito Y., Ishizaki T., Sasaki F., Ameshima S., Miyamori I. Leukotoxin and its diol induce neutrophil chemotaxis through signal transduction different from that of fMLP. Eur Respir J 2000, 15:75-79.
45. Sisemore M. Cellular characterization of leukotoxin diol-induced mitochondrial dysfunction. Arch Biochem Biophys 2001, 392:32-37.
46. Obinata H., Izumi T. G2A as a receptor for oxidized free fatty acids. Prostaglandins Other Lipid Mediat 2009, 89:66-72.
47. Hattori T., Obinata H., Ogawa A., Kishi M., Tatei K., Ishikawa O., et al. G2A plays proinflammatory roles in human keratinocytes under oxidative stress as a receptor for 9-hydroxyoctadecadienoic acid. J Invest Dermatol 2007, 128:1123-1133.
48. Emerson M.R., LeVine S.M. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 2004, 1021:140-145.
49. Belvisi M.G., Mitchell J.A., Targeting P.P.A.R. receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol 2009, 158:994-1003.
50. Altmann R., Hausmann M., Spöttl T., Gruber M., Bull A.W., Menzel K., et al. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells. Biochem Pharmacol 2007, 74:612-622.
51. Stoll L.L., Morland M.R., Spector A.A. 13-HODE increases intracellular calcium in vascular smooth muscle cells. Am J Physiol 1994, 266:C990-C996.
52. Fritsche K.L. Too much linoleic acid promotes inflammation-doesn't it?. Prostaglandins Leukot Essent Fatty Acids 2008, 79:173-175.
53. Schulze-Tanzil G., de S.P., Behnke B., Klingelhoefer S., Scheid A., Shakibaei M. Effects of the antirheumatic remedy hox alpha - a new stinging nettle leaf extract - on matrix metalloproteinases in human chondrocytes in vitro. Histol Histopathol 2002, 17:477-485.
54. Chiang N., Bermudez E.A., Ridker P.M., Hurwitz S., Serhan C.N. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA 2004, 101:15178-15183.
55. Powell W.S. Extraction of eicosanoids from biological fluids, cells, and tissues. Methods Mol Biol 1999, 120:11-24.
56. Deems R., Buczynski M.W., Bowers Gentry R., Harkewicz R., Dennis E.A. Detection and quantitation of eicosanoids via high performance liquid chromatography-electrospray ionization-mass spectrometry. Methods Enzymol 2007, 432:59-82.
57. Hall L.M., Murphy R.C. Electrospray mass spectrometric analysis of 5-hydroperoxy and 5-hydroxyeicosatetraenoic acids generated by lipid peroxidation of red blood cell ghost phospholipids. J Am Soc Mass Spectrom 1998, 9:527-532.
58. O'Donnell V.B., Maskrey B., Taylor G.W. Eicosanoids: generation and detection in mammalian cells. Methods Mol Biol 2008, 462:5-23.
59. Yang R., Chiang N., Oh S.F., Serhan C.N. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes 2001, John Wiley & Sons, Inc., Hoboken, NJ, USA.
60. Aderem A.A., Cohen D.S., Wright S.D., Cohn Z.A. Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. J Exp Med 1986, 164:165-179.
61. Dennis E.A., Deems R.A., Harkewicz R., Quehenberger O., Brown H.A., Milne S.B., et al. A mouse macrophage lipidome. J Biol Chem 2010, 285:39976-39985.
62. Buczynski M.W., Stephens D.L., Bowers-Gentry R.C., Grkovich A., Deems R.A., Dennis E.A. TLR-4 and sustained calcium agonists synergistically produce eicosanoids independent of protein synthesis in RAW264.7 cells. J Biol Chem 2007, 282:22834-22847.
63. Aderem A.A., Scott W.A., Cohn Z.A. Evidence for sequential signals in the induction of the arachidonic acid cascade in macrophages. J Exp Med 1986, 163:139-154.
64. Sabido E., Quehenberger O., Shen Q., Chang C.Y., Shah I., Armando A.M., et al. Targeted proteomics of the eicosanoid biosynthetic pathway completes an integrated genomics-proteomics-metabolomics picture of cellular metabolism. Mol Cell Proteomics 2012, 11:M111. 014746-6.
65. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
66. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
67. Dalli J., Serhan C.N. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 2012, 120:e60-e72.
68. Vance R.E., Isberg R.R., Portnoy D.A. Patterns of pathogenesis: discriminationof pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe 2009, 6:10-21.
69. Steere A.C., Coburn J., Glickstein L. The emergence of Lyme disease. J Clin Invest 2004, 113:1093-1101.
70. Steere A.C., Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol 2004, 4:143-152.
71. Blaho V.A., Buczynski M.W., Brown C.R., Dennis E.A. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J Biol Chem 2009, 284:21599-21612.
72. Falkow S., Isberg R.R., Portnoy D.A. The interaction of bacteria with mammalian cells. Annu Rev Cell Biol 1992, 8:333-363.
73. Chiang N., Fredman G., Bäckhed F., Oh S.F., Vickery T., Schmidt B.A., et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012, 484:524-528.
74. Bergsbaken T., Fink S.L., Cookson B.T. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009, 7:99-109.
75. Miao E.A., Leaf I.A., Treuting P.M., Mao D.P., Dors M., Sarkar A., et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol 2010, 11:1136-1142.
76. Moltke von J., Trinidad N.J., Moayeri M., Kintzer A.F., Wang S.B., Van Rooijen N., et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 2012, 490:107-111.
77. Young D., Hussell T., Dougan G. Chronic bacterial infections: living with unwanted guests. Nat Immunol 2002, 3:1026-1032.
78. O'Garra A., Redford P.S., McNab F.W., Bloom C.I., Wilkinson R.J., Berry M.P.R. The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
79. Kaufmann S.H.E. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol 2012, 33:373-379.
80. Müller B., Borrell S., Rose G., Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013, 29:160-169.
81. Tobin D.M., Vary J.C.V., Ray J.P., Walsh G.S., Dunstan S.J., Bang N.D., et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010, 140:717-730.
82. Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
83. Vance R.E., Hong S., Gronert K., Serhan C.N., Mekalanos J.J. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci USA 2004, 101:2135-2139.
84. Loo Y.-M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34:680-692.
85. Gurtler C., Bowie A.G. Innate immune detection of microbial nucleic acids. Trends Microbiol 2013, 21:413-420.
86. Kash J.C., Tumpey T.M., Proll S.C., Carter V., Perwitasari O., Thomas M.J., et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006, 443:578-581.
87. Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012, 76:16-32.
88. Yuen K.Y., Wong S.S. Human infection by avian influenza A H5N1. Hong Kong Med J 2005, 11:189-199.
89. Morita M., Kuba K., Ichikawa A., Nakayama M., Katahira J., Iwamoto R., et al. The lipid mediator protectin D1 Inhibits influenza virus replication and improves severe influenza. Cell 2013, 153:112-125.
90. Tam V.C., Quehenberger O., Oshansky C.M., Suen R., Armando A.M., Treuting P.M., et al. Lipidomic profiling of influenza infection identifies mediators that induceand resolve inflammation. Cell 2013, 154:213-227.
91. Levy B.D., Kohli P., Gotlinger K., Haworth O., Hong S., Kazani S., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 2007, 178:496-502.
92. Pillai P.S., Leeson S., Porter T.F., Owens C.D., Kim J.M., Conte M.S., et al. Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients. Inflammation 2012, 35:98-113.